MEDITE CANCER DIAGNOSTICS, INC. Business Development
MEDITE CANCER DIAGNOSTICS, INC. reported Business Development of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-05-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessDevelopment · last filed 2018-05-17
- MEDITE CANCER DIAGNOSTICS, INC. business development for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- MEDITE CANCER DIAGNOSTICS, INC. business development for fiscal 2016 was $234.00K.
- MEDITE CANCER DIAGNOSTICS, INC. business development for fiscal 2015 was $0.00.
| Period end | Business Development 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-05-17 |
| 2016-12-31 | $234.00K 10-K · filed 2018-05-17 |
| 2015-12-31 | $0.00 10-K · filed 2017-04-14 |